18+ • For Research & Educational Purposes Only • Not Medical Advice  Disclaimer
Peptide Wiki
Nootropic & NeurologicalPreclinical

Orexin-A

33 amino acid neuropeptide produced in the lateral hypothalamus that regulates wakefulness, alertness, appetite, and stress responses

Research Reality Check

Not Enough Evidence YetInteresting idea, but proof is still thin.
ClaimSome people claim Orexin-A has clear value for nootropic & neurological research.
RealityMost support is early or indirect, so human results are not settled.
Bottom LineUse the evidence score, sources, and safety notes before taking any claim seriously.
Why People Believe ThisSimple explanations and user stories can sound more certain than the research is.
Watch Out For
Guaranteed resultsExact protocols presented as provenAnecdotes used as proof
367Discussions
2Citations

Evidence Dossier

84Evidence

Preclinical

Evidence score reflects source depth, citations, and research maturity. It is not a medical recommendation.

2Citations
367Discussions
Start Here

Orexin-A at a glance

A fast read for beginners, with evidence strength, route context, safety depth, and community activity surfaced before the deeper sections.

Evidence score84Preclinical
Primary routeIntranasalRoute availability varies by context
Safety depthLimited dataReview safety notes before making assumptions
Community questions367Related discussions and experiences

Orexin-A (hypocretin-1) is a 33-amino acid neuropeptide produced exclusively by a small cluster of neurons in the lateral hypothalamus (LH). Together with its related peptide orexin-B (hypocretin-2), it exerts powerful wake-promoting effects through activation of two G-protein coupled receptors: OX1R (with selectivity for orexin-A) and OX2R (activated by both). Orexin signaling is essential for maintaining sustained wakefulness: loss of orexinergic neurons (as in narcolepsy type 1) leads to sudden uncontrollable sleep episodes and cataplexy.

How It Works

Beyond sleep-wake regulation, orexin-A is a central integrator of arousal, appetite, energy expenditure, stress response, reward circuitry, and autonomic function. It promotes noradrenergic, serotonergic, dopaminergic, and histaminergic neurotransmission - explaining its broad effects on alertness, motivation, and cognitive performance. Orexin-A levels are low during sleep and peak during active wakefulness and in response to novel environments or stressors.

Research interest in intranasal orexin-A administration has grown following studies showing that intranasal delivery can bypass the BBB and directly engage hypothalamic and brainstem orexin receptors. A key NASA-funded study demonstrated that intranasal orexin-A significantly reversed cognitive and performance deficits caused by sleep deprivation in rhesus macaques, approaching the efficacy of modafinil but through a more physiological mechanism. This has generated substantial interest in its potential for shift workers, military personnel, and narcolepsy treatment.

No human clinical trials of intranasal orexin-A for wakefulness promotion have been published, though suvorexant and lemborexant (orexin receptor antagonists) are FDA approved for insomnia, confirming the orexin axis as a validated pharmacological target. Human intranasal studies are at early exploratory stage.

Key Benefits

Powerful wake-promoting effects via OX1R/OX2R activation
Reverses cognitive deficits from sleep deprivation in primate models
Promotes alertness, motivation, and arousal without stimulant cardiotoxicity
Physiological mechanism distinct from amphetamines and modafinil
Potential therapeutic application in narcolepsy and excessive daytime sleepiness